Fiche société
Liu Qing
Traitements, essais et publications liés.
Traitements4programmes
Essais3liés
Publications4liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| OrelabrutinibDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique, SEP | Phase 1 | Immunomodulation | United States, Australia, Belgium, Bulgaria, Croatia, Czechia, Estonia, France, … | À vérifier |
| OrelabrutinibOrelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally. | SEP | Phase 3 | Immunomodulation | United States, Australia, Belgium, Bulgaria, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Italy, Lithuania, Poland, Puerto Rico, Romania, Serbia, Spain, Ukraine | À vérifier |
| OrelabrutinibOrelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally. | SEP | Phase 3 | Immunomodulation | United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Italy, Netherlands, Poland, Puerto Rico, Romania, Serbia, Slovakia, Spain, Ukraine | À vérifier |
| OrelabrutinibDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | Immunomodulation | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Orelabrutinib | Sclérose latérale amyotrophique | Phase 1 | NCT07875972 | Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS) | NOT_YET_RECRUITING |
| Orelabrutinib | SEP | Phase 3 | NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | RECRUITING |
| Orelabrutinib | SEP | Phase 3 | NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | RECRUITING |
Publications
4| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Orelabrutinib | A UHPLC-MS/MS method for the simultaneous quantification of BTK inhibitors and their active metabolite in human plasma and cerebrospinal fluid. | Bioanalysis | ||
| Orelabrutinib | Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report. | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | ||
| Orelabrutinib | Immune thrombocytopenia: Evolving mechanistic understanding and clinical development of new therapies. | Tzu chi medical journal | ||
| Orelabrutinib | Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. | Journal of cellular and molecular medicine |